Chronic Graft Versus Host Disease study: Dental Cleaning
Official title Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
ClinicalTrials.gov ID: NCT07535008
What this study is testing
- What it's testing
- The study wants to know whether a dental cleaning done shortly after a transplant can reduce the chance of developing chronic graft‑versus‑host disease.
- Who it's for
- People who are having an allogeneic hematopoietic (stem‑cell) transplant for blood cancers.
- What's involved
- Participants receive an additional professional dental cleaning soon after their transplant, along with the usual care, and will have follow‑up visits and exams to monitor for GVHD.
- Time commitment
- The study follows participants for several months after transplant, requiring the cleaning and a few scheduled clinic visits.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old
- T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed.
- 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor
- Cord blood
- Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)
You likely can't join if
- Edentulous state
- Bone marrow as graft source
- Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis
- Use of anti-thymocyte globulin (ATG) in conditioning
See the full eligibility criteria
- Age ≥ 18 years old
- T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed
- 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor
- Cord blood
- Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)
- Ability to understand and sign a written informed consent document (or legal representative)
- Edentulous state
- Bone marrow as graft source
- Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis
- Use of anti-thymocyte globulin (ATG) in conditioning
The study team makes the final eligibility decision.
Where it is enrolling
- Seattle, Washington, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Seattle, Washington, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.